{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:27:29Z","timestamp":1793039249951,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019378","name":"Concert Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019378","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jaad.2024.06.097","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T12:12:46Z","timestamp":1721736766000},"page":"880-888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)"],"prefix":"10.1016","volume":"91","author":[{"given":"Brett","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne M.","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha A.","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zirwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Maari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Sapra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Brzewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marni C.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cassella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2024.06.097_bib1","first-page":"59","article-title":"Alopecia areata - current understanding and management","volume":"20","author":"Lintzeri","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2024.06.097_bib2","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","article-title":"Burden of illness in alopecia creata: a cross-sectional online survey study","volume":"20","author":"Mesinkovska","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2024.06.097_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.18926","article-title":"The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity","author":"Muntyanu","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2024.06.097_bib4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/CCID.S309215","article-title":"A comprehensive literature review of JAK inhibitors in treatment of alopecia areata","volume":"14","author":"Dillon","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2024.06.097_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ajd.12913","article-title":"Systemic treatments for alopecia areata: a systematic review","volume":"60","author":"Lai","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2024.06.097_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.06.097_bib7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2024.06.097_bib10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.06.097_bib11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2024.06.097_bib12","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2024.06.097_bib13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224025507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224025507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:03:14Z","timestamp":1732845794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224025507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0190962224025507"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.06.097","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.06.097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}